- Latest available (Revised)
- Original (As made)
This is the original version (as it was originally made).
56.—(1) A relevant body must, in exercising its functions under or by virtue of section 3(1), 3A(1) or 3B of the 2006 Act, ensure that—
(a)a scheme product is supplied or administered in accordance with the scheme to a scheme patient,
(b)a scheme product continues to be supplied or administered in accordance with the scheme to a scheme patient where such a patient was receiving such a course of treatment immediately before the relevant date unless the patient’s consultant has determined, in consultation with the scheme patient, that the scheme product is no longer clinically appropriate;
(c)a scheme product is supplied or administered to a patient with multiple sclerosis for the purpose of that person’s treatment for that condition where that patient—
(i)is not a scheme patient, but
(ii)was, on 4th February 2002, and is, immediately before the relevant date, receiving such a course of treatment for that condition.
(2) In this Part—
“scheme” means the arrangement between the Department of Health (England), the National Assembly for Wales, the Scottish Ministers, the Northern Ireland Department of Health, Social Security and Public Safety, Biogen Idec Inc., Bayer PLC, Merck Serono Limited, and Teva Pharmaceutical Industries Limited together with Aventis Pharma Limited, dated 1st February 2002, for the supply and administration of products for the treatment of multiple sclerosis(1);
“scheme patient” means a patient with multiple sclerosis who is eligible to receive treatment under the scheme and who consents to receive such treatment;
“scheme product” means—
Interferon beta-1a: Avonex and Rebif (22mg and 44mg);
Interferon beta – 1b: Betaferon; or
Glatiramer acetate: Copaxone,
which is given for the treatment of multiple sclerosis and which is manufactured by a company that is a party to the scheme.
The arrangement can be found at www.dh.gov.uk/en/Publicationsandstatistics/Lettersandcirculars/ Healthservicecirculars/DH_4004332 – see Annex A.
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download.
Would you like to continue?
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: